The intraperitoneal (IP) delivery of ExSpeU1s-AAV9 particles successfully increased the production of the human ELP1 full-length transcript and protein in several mouse tissues, demonstrating that the ExSpeU1 approach would be a potential therapeutic option for FD. This evidence concerns the gene ELP1 and Fabry disease.